Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

Účinky MIB-626 s vysoce intenzivním multidimenzionálním tréninkovým programem i bez něj

3. listopadu 2026 aktualizováno: Shalender Bhasin, Metro International Biotech, LLC

Účinky MIB-626 (β-nikotinamid mononukleotid) s vysoce intenzivním multidimenzionálním cvičebním programem a bez něj na fyzickou výkonnost, svalovou bioenergetiku a neuropsychologický výkon u vysoce zdatných mladých dospělých

A single-center, randomized, placebo-controlled study in community dwelling, healthy, regularly exercising, highly physically fit men and women, 19 to 40 years. Eligible participants will be randomized to receive either 1000 mg NMN or placebo twice daily for 10 weeks.

Přehled studie

Postavení

Dokončeno

Podmínky

Intervence / Léčba

Detailní popis

The study participants will be screened for potential participation and those meeting eligibility criteria on screening will be offered participation in the study. 120 subjects will be block randomized in a 1:1:1:1 ratio, stratified by sex (male, female) and baseline VO2 max. Participants will be randomly assigned to one of four groups using a 2 by 2 factorial design: Group 1 - MIB-626 (MIB-626 - UPA) plus usual physical activity; Group 2 - standardized, progressive, high intensity, multidimensional exercise plus placebo (PL-Ex); Group 3 - MIB-626 plus standardized, progressive, high intensity, multidimensional exercise (MIB-626-Ex); Group 4 - placebo plus usual physical activity (PL-UPA).

Typ studie

Intervenční

Zápis (Aktuální)

124

Fáze

  • Fáze 2

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní místa

    • Massachusetts
      • Boston, Massachusetts, Spojené státy, 02115
        • Brigham and Women's Hospital

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

19 let až 40 let (Dospělý)

Přijímá zdravé dobrovolníky

Ano

Pohlaví způsobilá ke studiu

Všechno

Popis

Inclusion Criteria:

  1. Highly physically fit and familiar with high intensity exercise training, as indicated

    1. Engages in vigorous exercise regularly (4 or more days each week) for 30 minutes or longer and which includes elements of resistance exercise training
    2. Physically fit ascertained using Daniels' equation https://runsmartproject.com/calculator/, 5K time: ≤ 23.0 min, and/ or 10K time: ≤ 48.0 min These criteria will maximize the likelihood of including individuals with VO2max of at least 40 mL/kg/min.
  2. Has a body mass index (BMI) between 18.5 and 32 kg/m2, inclusive

  3. Willingness to engage in 10-weeks of intensive exercise training designed to improve aerobic capacity and endurance, muscle strength, power, and fatigability, anaerobic capacity, and body composition, and to reduce fatigue

  4. Willing to not engage in additional exercise training if randomized to the progressive exercise group and willing to not change usual physical activity if assigned to the usual physical activity group

  5. Is free from clinically significant medical problems as determined by the Investigator

  6. Is capable of providing written informed consent.

  7. Is willing and able to provide authorization for the use and disclosure of personal health information in accordance with Health Insurance Portability and Accountability Act (HIPAA).

In addition, female participants must:

1. Not be pregnant and not planning to become pregnant over the next 6 months

Exclusion Criteria:

  1. Has AST or ALT > 2 times the upper limit of normal

  2. Hematocrit < 36% or > 50% for men, or < 35% to > 48% for women

  3. Has a diagnosis of diabetes or is using diabetes medications or has an A1C > 6.4%

  4. Serum creatinine > 2.0 mg/dL or eGFR <60 mL/min

  5. Prohibited medications and substances:

    a. Use of any performance enhancing substance (anabolic steroids, rhGH, DHEA, androstenedione, or any other performance enhancing drug

  6. Current use of opiates, amphetamine, cannabinoids and cocaine

    1. Use of any other dietary supplement during the course of the trial. Subjects who are using a supplement containing nicotinamide or niacin or nicotinamide riboside may be included if they agree to stop the supplement at least 2 weeks prior to randomization and agree not to use such supplement/s during the entire duration of the study.
    2. Initiation of a new pharmaceutical product during the preceding 3 months
  7. Known allergy to niacin or nicotinamide mononucleotide

  8. In the judgment of the study physician, the participant is unlikely to comply with the study protocol for any reason or it may not be safe to administer the study.

  9. Competing in organized athletics (e.g., collegiate sports) or training in preparation for competition

  10. Contraindications to magnetic resonance imaging (MRI) and magnetic resonance spectroscopy (MRS). These include: a) electrical implants such as cardiac pacemakers b) ferromagnetic implants such as aneurysm clips, surgical clips, artificial hearts valves with steel parts, shrapnel or steel implants c) ferromagnetic objects such as jewelry or metal clips in clothing d) pre-existing history of claustrophobic reactions. (Some participants who cannot undergo MRI/MRS but can undergo other study procedures might be considered on a case-by-case basis)

For women only:

  1. Pregnant or planning to get pregnant over the next 6 months
  2. Use of oral contraceptives is allowed provided the contraceptive regimen was initiated at least 3 months before randomization and the participant agrees not to change the regimen during the course of the study. 6.3 Excluded Medications and Treatments

1. The ingestion of the following is prohibited during 14 days prior to Day 0 and for the duration of the intervention period:

  • Multivitamin preparations that contain niacin or one of its metabolites
  • Products that contain niacin, nicotinic acid, nicotinamide in any form, other than natural foods
  • Herbal supplements 2. Treatment with another investigational drug, investigational device, or approved therapy for investigational use within 3 month is prohibited.

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

  • Primární účel: Léčba
  • Přidělení: Randomizované
  • Intervenční model: Faktorové přiřazení
  • Maskování: Čtyřnásobek

Zbraně a zásahy

Skupina účastníků / Arm
Intervence / Léčba
Aktivní komparátor: Investigational Product - MIB 626 plus usual physical activity (MIB-626- UPA)

The MIB-626 will be a GMP-grade microcrystalline solid NMN mixed with inert excipients (including microcrystalline cellulose) and compressed into tablets at a dose strength of 500 mg per tablet, enabling administration of the 1,000 mg twice daily using two tablets taken twice daily.

The MIB-626 will be a GMP-grade microcrystalline solid NMN mixed with inert excipients (including microcrystalline cellulose) and compressed into tablets at a dose strength of 500 mg per tablet, enabling administration of the 1,000 mg twice daily using two tablets taken twice daily.

Ostatní jména:
  • Výzkumný produkt

Participants will be asked to perform usual physical activity per listed in the protocol

Komparátor placeba: Placebo plus usual physical activity (PL-UPA)

Matching placebo tablets will be provided by the study's Sponsor, Metro International Biotech, LLC.

Participants will be asked to perform usual physical activity per listed in the protocol

Placebo - Participants randomized to placebo will receive Matching placebo tablets will be provided by Metro International Biotech, LLC

Aktivní komparátor: MIB-626 plus standardized, progressive, high intensity, multidimensional exercise (MIB-626-Ex)

The MIB-626 will be a GMP-grade microcrystalline solid NMN mixed with inert excipients (including microcrystalline cellulose) and compressed into tablets at a dose strength of 500 mg per tablet, enabling administration of the 1,000 mg twice daily using two tablets taken twice daily.

The MIB-626 will be a GMP-grade microcrystalline solid NMN mixed with inert excipients (including microcrystalline cellulose) and compressed into tablets at a dose strength of 500 mg per tablet, enabling administration of the 1,000 mg twice daily using two tablets taken twice daily.

Ostatní jména:
  • Výzkumný produkt

Participants will be asked to perform high intensity, standardized, progressive, multidimensional exercise.

Komparátor placeba: Standardized, progressive, high intensity, multidimensional exercise plus placebo (PL-Ex)

Matching placebo tablets will be provided by the study's Sponsor, Metro International Biotech, LLC.

Placebo - Participants randomized to placebo will receive Matching placebo tablets will be provided by Metro International Biotech, LLC

Participants will be asked to perform high intensity, standardized, progressive, multidimensional exercise.

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Change in Aerobic capacity from baseline to week 11, identified as VO2 max measured during a standardized increasing work rate treadmill protocol
Časové okno: 11 Weeks

To determine the effects of MIB-626 (microcrystalline β-Nicotinamide Mononucleotide), administered at a dose of 1000-mg twice daily for 10 weeks, with and without a standardized multidimensional program of progressive high intensity exercise training on aerobic capacity, assessed as VO2 max measured during a standardized increasing work rate treadmill protocol, in community living, healthy, regularly exercising, highly physically fit, men and women, 19 to 40 years, inclusive.

11 Weeks

Sekundární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Change in endurance time from baseline to week 11, measured during a constant work rate test
Časové okno: 11 weeks

To determine the effects of MIB-626, administered at a dose of 1000-mg twice daily for 10 weeks, with and without a standardized multidimensional program of progressive high intensity exercise training, on endurance time during a constant work rate test.

11 weeks
Change from baseline to week 11 in anaerobic threshold during CPXT
Časové okno: 11 weeks

To determine the effects of MIB-626 administered twice daily for 10 weeks, with and without a standardized multidimensional program of progressive high intensity exercise training on anaerobic threshold by assessing peak anaerobic power, average anaerobic capacity, rate of power decay, and fatigue index using the Wingate anaerobic power test.

11 weeks
Change in upper body muscle performance, assessed as change from baseline to week 10
Časové okno: 10 weeks

To determine the effects of MIB-626, administered twice daily for 10 weeks, with and without a standardized multidimensional program of progressive high intensity exercise training on upper body muscle performance using the instrumented chest press machines (Keiser).

10 weeks
Change in lower body muscle performance, assessed as change from baseline to week 10
Časové okno: 10 weeks

To determine the effects of MIB-626, administered twice daily for 10 weeks, with and without a standardized multidimensional program of progressive high intensity exercise training on lower body muscle performance using the instrumented Keiser leg press machines.

10 weeks
Change over the 10 weeks in performance scores on sustained-attention, reaction-timed task
Časové okno: 10 weeks

To determine the effects of MIB-626, administered twice daily for 10 weeks, with and without a standardized multidimensional program of progressive high intensity exercise training on sustained-attention, reaction-timed task that measures the speed with which subjects respond to a visual stimulus using a standardized Psychomotor Vigilance Task test.

10 weeks
Change over 10 weeks in working memory and working memory capacity
Časové okno: 10 weeks

To determine the effects of MIB-626, administered twice daily for 10 weeks, with and without a standardized multidimensional program of progressive high intensity exercise training on working memory and working memory capacity during a standardized continuous performance task assessed by using the n back test

10 weeks
Change over 10 weeks in selective attention, target identification and response
Časové okno: 10 weeks

• To determine the effects of MIB-626, administered twice daily for 10 weeks, with and without a standardized multidimensional program of progressive high intensity exercise training on selective attention, target identification and response (delay in reaction time between congruent and incongruent stimuli) using the STROOP test.

10 weeks
Change over 10 weeks in total sleep time
Časové okno: 10 weeks

To determine the effects of MIB-626 administered twice daily for 10 weeks, with and without a standardized multidimensional program of progressive high intensity exercise training on total sleep time measured using an Actigraph device

10 weeks
Change from baseline in insulin sensitivity
Časové okno: 10 weeks

To determine the effects of MIB-626 on insulin sensitivity by assessing fasting glucose, insulin and a derived index of insulin sensitivity by using (HOMA-IR)

10 weeks
Changes from baseline in blood lipid profile
Časové okno: 10 weeks.

To evaluate the physiologic effects of MIB-626 on blood lipid profile by assessing the levels of plasma lipids, free fatty acids, leptin, myostatin, and adiponectin in the blood.

10 weeks.
Change from baseline in sleep latency
Časové okno: 10 weeks

and without a standardized multidimensional program of progressive high intensity exercise training on sleep latency measured using an Actigraph

10 weeks

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Sponzor

Vyšetřovatelé

  • Vrchní vyšetřovatel: Shalender Bhasin, MD, Brigham and Women's Hospital

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia (Aktuální)

25. října 2023

Primární dokončení (Aktuální)

17. června 2025

Dokončení studie (Aktuální)

4. srpna 2025

Termíny zápisu do studia

První předloženo

1. března 2023

První předloženo, které splnilo kritéria kontroly kvality

17. května 2023

První zveřejněno (Aktuální)

26. května 2023

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

9. listopadu 2026

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

3. listopadu 2026

Naposledy ověřeno

1. září 2025

Více informací

Termíny související s touto studií

Další identifikační čísla studie

  • MIB-626-206

Plán pro data jednotlivých účastníků (IPD)

Plánujete sdílet data jednotlivých účastníků (IPD)?

NE

Popis plánu IPD

Individual participant data will not be shared

Informace o lécích a zařízeních, studijní dokumenty

Studuje lékový produkt regulovaný americkým FDA

Ano

Studuje produkt zařízení regulovaný americkým úřadem FDA

Ne

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .